CA3155861A1 - Methods of improving exercise performance, single ventricular performance, and myocardial performance index (mpi) in single ventricle heart disease, using udenafil compositions - Google Patents

Methods of improving exercise performance, single ventricular performance, and myocardial performance index (mpi) in single ventricle heart disease, using udenafil compositions

Info

Publication number
CA3155861A1
CA3155861A1 CA3155861A CA3155861A CA3155861A1 CA 3155861 A1 CA3155861 A1 CA 3155861A1 CA 3155861 A CA3155861 A CA 3155861A CA 3155861 A CA3155861 A CA 3155861A CA 3155861 A1 CA3155861 A1 CA 3155861A1
Authority
CA
Canada
Prior art keywords
patient
svhd
udenafil
fontan
vat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3155861A
Other languages
English (en)
French (fr)
Inventor
James L. Yeager
David J. Goldberg
Stephen M. Paridon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mezzion Pharma Co Ltd
Children's Hospital of Philadelphia
Original Assignee
Mezzion Pharma Co Ltd
Children's Hospital of Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mezzion Pharma Co Ltd, Children's Hospital of Philadelphia filed Critical Mezzion Pharma Co Ltd
Publication of CA3155861A1 publication Critical patent/CA3155861A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3155861A 2019-09-24 2020-05-12 Methods of improving exercise performance, single ventricular performance, and myocardial performance index (mpi) in single ventricle heart disease, using udenafil compositions Pending CA3155861A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962905350P 2019-09-24 2019-09-24
US62/905,350 2019-09-24
US201962936497P 2019-11-16 2019-11-16
US62/936,497 2019-11-16
US202063023070P 2020-05-11 2020-05-11
US63/023,070 2020-05-11
PCT/US2020/032493 WO2021061203A1 (en) 2019-09-24 2020-05-12 Methods of improving exercise performance, single ventricular performance, and myocardial performance index (mpi) in single ventricle heart disease, using udenafil compositions

Publications (1)

Publication Number Publication Date
CA3155861A1 true CA3155861A1 (en) 2021-04-01

Family

ID=75167062

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3155861A Pending CA3155861A1 (en) 2019-09-24 2020-05-12 Methods of improving exercise performance, single ventricular performance, and myocardial performance index (mpi) in single ventricle heart disease, using udenafil compositions

Country Status (7)

Country Link
US (1) US12576081B2 (cg-RX-API-DMAC10.html)
EP (1) EP4041242A4 (cg-RX-API-DMAC10.html)
JP (2) JP2022550734A (cg-RX-API-DMAC10.html)
AU (1) AU2020356193B2 (cg-RX-API-DMAC10.html)
CA (1) CA3155861A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022003593A (cg-RX-API-DMAC10.html)
WO (1) WO2021061203A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023009537A1 (en) * 2021-07-26 2023-02-02 Longeveron Inc. Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome
AU2022419178A1 (en) * 2021-12-20 2024-08-08 Mezzion Pharma Co., Ltd. Methods and compositions for improving exercise performance
EP4785873A1 (en) 2025-01-30 2026-08-05 SonoFit AS Wearable fitness devices and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272741A1 (en) * 2004-01-16 2005-12-08 Jack Rychik Novel methods of treatment for Fontan patients with protein losing enteropathy
WO2005094521A2 (en) * 2004-03-23 2005-10-13 Georgia Tech Research Corporation Anatomical connection
EP1888074B1 (en) 2005-06-10 2011-12-21 Dong-A Pharmaceutical Co., Ltd. Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative
CA2623657A1 (en) 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
KR100792126B1 (ko) 2006-04-04 2008-01-04 동아제약주식회사 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제
KR101002490B1 (ko) 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
JP2010532319A (ja) 2007-06-13 2010-10-07 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 聴覚障害の処置用のｐｄｅ阻害剤
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101071877B1 (ko) 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
DK2512479T3 (en) 2009-12-18 2016-06-06 Exodos Life Sciences Ltd Partnership Compositions for the treatment of peripheral vascular disease
EP2556820A4 (en) 2010-04-05 2015-01-21 Sk Chemicals Co Ltd COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
JP5883687B2 (ja) 2011-03-09 2016-03-15 第一三共ヘルスケア株式会社 Ｐｄｅ５阻害剤含有医薬組成物
KR101383430B1 (ko) 2012-01-26 2014-04-08 광동제약 주식회사 새로운 조합의 구강내 속붕해 필름형성 조성물 및 ｐｄｅ５ 저해제가 함유된 구강내 속붕해 필름제제
BR112015010947A2 (en) 2012-11-13 2018-06-05 Nusirt Sciences, Inc. compositions and methods for increasing energy metabolism.
MX390977B (es) 2014-08-12 2025-03-21 Mezzion Pharma Co Ltd Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo

Also Published As

Publication number Publication date
AU2020356193A1 (en) 2022-05-19
JP2022550734A (ja) 2022-12-05
US12576081B2 (en) 2026-03-17
EP4041242A1 (en) 2022-08-17
WO2021061203A1 (en) 2021-04-01
EP4041242A4 (en) 2023-10-18
AU2020356193B2 (en) 2026-06-11
JP2025118624A (ja) 2025-08-13
MX2022003593A (es) 2022-09-19
US20240197736A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
US20140288079A1 (en) Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
FI4243825T3 (fi) Omekamtiivimekarbiili sydämen vajaatoiminnan hoitoon valikoiduilla potilasryhmillä
Sharpe et al. Nitroglycerin in a transdermal therapeutic system in chronic heart failure
JP2022550734A5 (cg-RX-API-DMAC10.html)
RU2144783C1 (ru) Способ подбора препаратов для лечения артериальной гипертонии
JP2007517911A (ja) 心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法
EP2435047B1 (en) Angina treatment
JP5396387B2 (ja) 心臓不整脈を治療するためのｄ−リボースの用途
Harper et al. The acute and chronic haemodynamic effects of prazosin in severe congestive cardiac failure
Guazzi Sildenafil and phosphodiesterase-5 inhibitors for heart failure
Douglas Jr Hemodynamic effects of nifedipine in primary pulmonary hypertension
Takenaka et al. Effects of rapid saline infusion on orthostatic intolerance and autonomic tone after 20 days bed rest
Çilingiroğlu et al. Large pericardial effusion induced by minoxidil
Faerchtein et al. A placebo controlled trial of the alpha-blocker, indoramin, in the treatment of arterial hypertension
Kataoka et al. Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol
Galea et al. Sildenafil in acute pulmonary embolism: case report and review of literature
Stanek et al. Dose-effect relationships of prostaglandin E1 in severe endstage chronic heart failure
Evans et al. The effects of long term methyldopa in patients with hypoxic cor pulmonale
Bussmann et al. Controlled study of intravenous nitroglycerin treatment for two days in patients with recent myocardial infarction
RU2310457C1 (ru) Способ лечения артериальной гипертензии
Ibrahim et al. Hemodynamic effects of SIN-1 in acute left heart failure
RU2164410C2 (ru) Способ лечения первичной артериальной гипертензии
Ahmadi-Simab et al. Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost
Maki et al. Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension
Mehairy et al. Nadolol and propranolol in the treatment of hypertension: a double-blind comparison

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240513

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250502

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250508

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250908

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260508

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260508

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260708